Masimo (NASDAQ:MASI) Issues Earnings Results, Beats Estimates By $0.12 EPS

Masimo (NASDAQ:MASI) released its quarterly earnings results on Tuesday. The medical equipment provider reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12, Zacks reports. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.During the same period in the prior year, the company posted $0.86 EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. Masimo updated its FY 2025 guidance to 5.620-5.790 EPS.

Masimo Price Performance

NASDAQ:MASI traded up $4.05 during trading hours on Tuesday, reaching $149.01. The stock had a trading volume of 1,439,977 shares, compared to its average volume of 639,871. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. Masimo has a 52 week low of $133.70 and a 52 week high of $194.88. The company has a 50 day moving average price of $144.91 and a two-hundred day moving average price of $154.05. The stock has a market capitalization of $8.09 billion, a PE ratio of -17.49 and a beta of 1.28.

Insider Transactions at Masimo

In other news, Director William R. Jellison acquired 3,000 shares of Masimo stock in a transaction on Monday, August 11th. The shares were acquired at an average price of $145.98 per share, with a total value of $437,940.00. Following the purchase, the director directly owned 4,790 shares in the company, valued at $699,244.20. The trade was a 167.60% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.70% of the stock is currently owned by insiders.

Institutional Trading of Masimo

A number of large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Masimo by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after purchasing an additional 66 shares during the period. Orion Porfolio Solutions LLC raised its stake in shares of Masimo by 2.2% in the second quarter. Orion Porfolio Solutions LLC now owns 4,871 shares of the medical equipment provider’s stock valued at $819,000 after acquiring an additional 104 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Masimo by 12.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 166 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Masimo by 1.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 10,596 shares of the medical equipment provider’s stock worth $1,782,000 after purchasing an additional 177 shares during the period. Finally, Amundi grew its holdings in Masimo by 1.0% during the 2nd quarter. Amundi now owns 41,583 shares of the medical equipment provider’s stock valued at $7,125,000 after purchasing an additional 416 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on MASI shares. BTIG Research reaffirmed a “buy” rating and issued a $198.00 price objective on shares of Masimo in a research note on Thursday, September 11th. Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Piper Sandler raised their price objective on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $194.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.